Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.
28 August, 2013
Adimab, LLC, a leader in the discovery of monoclonal and bispecific antibodies, and Innovent, a leading Chinese antibody therapeutics and manufacturing company, today announced a new partnership for the discovery, development and commercialization of an antibody-based therapeutic program. Under the terms of the Agreement, Adimab will utilize its antibody discovery and optimization platform to identify a fully human therapeutic antibody against a target selected by Innovent. All initial product development, including manufacturing and clinical trials, will be coordinated by Innovent. Both companies will retain rights to develop and commercialize the therapeutic program in their respective geographic territories.
23 August, 2013
The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, is pleased to announce that it has helped one of its members secure new facilities at the Stevenage Bioscience Catalyst, the UK's first open innovation bioscience campus, pioneering a unique culture to drive early stage biotech, pharma and medtech developments.
22 August, 2013
Tecan will be giving drug discovery scientists from across Europe the opportunity to discuss the latest trends in laboratory automation at this year’s autumn exhibitions. The Company has enjoyed close links with the drug discovery sector for over 30 years and, as a world leading supplier of automated liquid handling solutions, will be attending both ELRIG Drug Discovery 2013 and MipTec 2013 as part of its ongoing dedication to innovation in drug discovery.
19 August, 2013
Sunovion Pharma and San Diego-based drug discovery platform company Afraxis have entered into a partnership agreement to use the unique enhanced spine platform (ESP), to boost Sunovion’s preclinical central nervous system (CNS) drug discovery process.
16 August, 2013
Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that it has entered into a collaboration with Pfizer Inc. to identify new therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes.
14 August, 2013
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.
03 August, 2013
Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, The Institute of Cancer Research, London, and , Merck Serono, a division of Merck KGaA, Darmstadt, Germany, have signed a licensing deal today extending a successful initial alliance to discover and develop anticancer drugs that block the WNT signalling pathway.
02 August, 2013